Factors associated with non-treatment of hypertension and gender differences at baseline in the ELSA-Brasil cohort

The treatment of arterial hypertension (AH) contributes to the reduction of morbidity and mortality. Gender differences are likely to play a role, as non-treatment is associated with clinical and sociodemographic aspects. The aim of this study was to investigate the factors associated with non-treatment of AH and gender differences in hypertensive individuals from the ELSA-Brasil cohort. The study was conducted with 5,743 baseline hypertensive cohort participants. AH was considered if there was a previous diagnosis or if systolic blood pressure (SBP) was ≥140 and/or diastolic BP (DBP) was ≥90 mmHg. Sociodemographic and anthropometric data, lifestyle, comorbidities, and use of antihypertensive medications were evaluated through interviews and in-person measurements. Treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) or other antihypertensive medications and non-treatment were evaluated with multivariate logistic regression. Non-treatment was observed in 32.8% of hypertensive individuals. Of the 67.7% treated individuals, 41.1% received RAASi. Non-treatment was associated with alcohol consumption in women (OR=1.41; 95%CI: 1.15-1.73; P=0.001), lowest schooling level in men (OR=1.70; 95%CI: 1.32-2.19; P<0.001), and younger age groups in men and women (strongest association in males aged 35-44 years: OR=4.58, 95%CI: 3.17-6.6, P<0.001). Among those using RAASi, a higher proportion of white, older individuals, and with more comorbidities was observed. The high percentage of non-treatment, even in this civil servant population, indicated the need to improve the treatment cascade for AH. Public health policies should consider giving special attention to gender roles in groups at higher risk of non-treatment to reduce inequities related to AH in Brazil.

Lo clásico y lo nuevo en el tratamiento del sobrepeso y la obesidad / The classic and the new in the treatment of overweight and obesity

Así como planteamos en la primera entrega de esta serie de artículos de actualización sobre la obesidad, resulta urgente revisar el abordaje tradicional que la comunidad médica le ofrece a las personas con cuerpos gordos. En este segundo artículo desarrollaremos en profundidad diferentes alternativas terapéuticas para los pacientes que desean bajar de peso:plan alimentario, actividad física, tratamiento farmacológico y cirugía metabólica. (AU)

As we proposed in the first issue of this series of articles, it is urgent to review the traditional approach that the medical community offers to people with fat bodies. This second article will develop different therapeutic alternatives for patients who want to lose weight: eating plans, physical activity, pharmacological treatment, and metabolic surgery. (AU)

Resultados além do gerenciamento da infecção em um serviço de Gerenciamento da Terapia Medicamentos para pessoas vivendo com HIV

Avaliar os resultados clínicos de serviços de gerenciamento da terapia medicamentosa (GTM) oferecidos a pessoas vivendo com HIV (PVHIV) em uma unidade de dispensação de medicamentos brasileira. O estudo foi dividido em uma etapa transversal (etapa I), que avaliou o fator associado à identificação de dois ou mais problemas relacionados ao uso de medicamentos (PRM) na avaliação inicial; e uma etapa quasi- experimental (etapa II), realizada com um único grupo de pacientes para avaliar desfechos clínicosForam acompanhadas 52 PVHIV. A média de idade foi de 60±11,3 anos (min. = 29; máx. =78). A presença de dislipidemia (OR=5,38; IC 95%=1,61-17,97; p=0,006) e o uso de sete ou mais medicamentos (OR=4,28; IC 95%=1,32-13,88; p=0,015) foram fatores associados a identificação de dois ou mais PRM. Foi demonstrada uma diferença significativa entre os valores iniciais e finais de pressão arterial sistólica, carga viral do HIV, contagem de células T CD4+ e triglicerídeos (p<0,05). O serviço de GTM favoreceu os desfechos clínicos positivos.

To assess the clinical outcomes of comprehensive medication management (CMM) services offered to people living with HIV (PLHIV) at a Brazilian Antiretroviral Medication Dispensing Unit. The study was divided into a cross-sectional stage (stage I), to evaluate associated factor with the identification of two or more drug therapy problems (DTP) in the initial assessment; and a quasi-experimental stage (stage II), conducted with a single group of PLHIV to evaluate clinical outcomes. A total of 52 PLHIV, with 60±11.3 years of age were followed up. In stage I, the presence of dyslipidemia (OR=5.38; 95%CI=1.61-17.97) and the use of seven or more medications (OR=4.28; 95% CI=1.32-13.88) were factors associated with the identification of DTP. In stage II, a significant difference was demonstrated between the initial and final values of systolic blood pressure, triglycerides, HIV viral load and CD4+T-cells count (p<0,05). The CMM service favored positive clinical outcomes.

The practice of clinical pharmacists participating in the management of prophylactic antibiotics during the perioperative period of thoracic surgery / 中国基层医药

Objective:To explore the role of clinical pharmacists participating in the management of prophylactic antibiotics during the perioperative period of thoracic surgery, and to evaluate the effects after participating in the practice.Methods:The use of antimicrobials during the perioperative period of thoracic surgery in Wenjiang Hospital of Sichuan Provincial People's Hospital in August 2019 (pre-practice) was retrospectively analyzed. The existing problems were summarized, and the possible causes of the existing problems were analyzed. The improvement measures were jointly developed by clinical pharmacists and physicians. Clinical pharmacists continued to manage the use of antimicrobials by means of medication order reviews, ward rounds for pharmacy service, and medication training. The use of prophylactic antibiotics during the perioperative period of thoracic surgery was compared between August 2019 (pre-practice group) and December 2019 (post-practice group) and the practical effect was evaluated.Results:Clinical pharmacists reviewed perioperative patients' medication orders once a day, ward rounds for pharmacy service twice a week, and medication training once a month. Twenty-two patients were enrolled before practice, and 26 patients were enrolled after practice. There were no significant differences in age, sex, body weight, operative time, type of surgical incision, and preventive use of antibiotics between the two groups (all P > 0.05). In the post-practice group, the appropriate time for preoperative administration was 100.0%, which was significantly higher than 88.2% in the pre-practice group. The reasonable rate of preoperative preventive drug selection was 100.0%, which was significantly higher than 44.4% in the pre-practice group ( χ2 = 17.50, P < 0.001). In the post-practice group, the duration of preventive medication was (1.82 ± 0.59) days, which was significantly shorter than (7.54 ± 3.25) days in the pre-practice group ( t = 11.97, P < 0.001). In the post-practice group, the cost of antibacterial drugs was 316.00(237.00,454.25) yuan, which was significantly lower than 1 136.00(391.81 , 2 184.65) yuan in the pre-practice group ( Z = -2.78, P < 0.05). The defined daily dose of antibiotics among inpatients was 2.67(2.00,3.42), which was significantly lower than 8.88(3.92 , 19.18) in the pre-practice group ( Z = -3.26, P < 0.05). There were no significant differences in the incidence of postoperative pulmonary infection and total length of hospital stay between the two groups (both P > 0.05). Conclusion:Clinical pharmacists participating in the management practice of perioperative prophylactic antibiotics in thoracic surgery can effectively promote the rational application of perioperative antibiotics, markedly improve the reasonable rate of prophylactic drug delivery, shorten the course of prophylactic drugs, reduce the cost of antibiotics, decrease the defined daily dose of antibiotics, without increasing the risk of postoperative pulmonary infection and the total length of hospital stay.

Clinical features and treatment status of adolescent patients with bipolar disorder / 四川精神卫生

BackgroundGender and age differences in the clinical manifestations of patients with bipolar disorder can affect the clinical diagnosis and treatment process. The current treatment effect of bipolar disorder in adolescents is not ideal， which has become the main reason for disability during the learning period. ObjectiveTo analyze the clinical features and medication therapy status of bipolar disorder in adolescents， and to provide references to support for personalized diagnosis and treatment. MethodsOn January 16， 2023， 1 169 patients with bipolar disorder who were hospitalized at Beijing Anding Hospital Affiliated Capital Medical University from January 1， 2014 to December 31， 2017 were retrospectively enrolled. Medical records were collected and analyzed to compare the clinical features among patients of different gender and age groups， and to explore the differences in medication use among patients of different genders in different types of seizures. ResultsMale patients reported a larger proportion of manic episodes， and a smaller proportion of depressive episodes than female patients （P<0.05）.Female patients reported a larger proportion of non-suicidal self-harm behaviors than male patients （χ2=7.761， P<0.01）.And patients in low-age group featured a larger proportion of mixed seizures， impulsive behaviors and family history of bipolar disorders along with a smaller proportion of manic episodes than those in high-age group （P<0.05 or 0.01）. High-age group had a longer average length of hospital stay than low-age group （t=-2.930， P<0.01）. In manic episode patients， males were found to have a larger proportion of valproate and atypical antipsychotic drug administration than females （P<0.01）. Among atypical antipsychotic drugs， males accounted for a larger proportion of administration of risperidone and olanzapine （χ2=26.957） than females （P<0.05 or 0.01）， while females constituted a larger proportion of administration of quetiapine （χ2=14.865） and aripiprazole than males （P<0.01）. In depressive episode patients， females had a larger proportion of administration of olanzapine than males （P<0.01）. In patients with mixed seizures， females occupied a larger proportion of administration of lithium carbonate than males （χ2=9.253， P<0.01）， and males exhibited a larger proportion of administration of valproate than females （P<0.05）. ConclusionDifferences have been shown in diagnostic classification and concomitant symptoms among adolescent bipolar disorder of different genders and ages. Furthermore， medications of lithium carbonate， valproate， atypical antipsychotic and other drugs differ by gender among adolescents of different subtypes of bipolar disorder. ［Funded by Key Special Project of the National Key R&D Program of the Ministry of Science and Technology for "Major Chronic Non communicable Disease Prevention and Control Research" （number， 2017YFC1311101）］

Uso inadecuado del fármaco acenocumarol en la fibrilación auricular no valvular

Introducción: El uso del acenocumarol como anticoagulante, constituye un aporte al tratamiento de la fibrilación auricular no valvular. En la actualidad existen otros tipos de anticoagulantes que no requieren control tan exhaustivo de la prueba digital International Normaizedl Ratio y tienen menos efectos secundarios. España es uno de los pocos países de Europa que continúa indicando acenocumarol, de forma similar a la warfarina. Tanto es así, que a los médicos de atención primaria no se les permite prescribir otros anticoagulantes más eficaces y menos molestos, para el paciente al realizar la prueba digital. Objetivo: Analizar el uso inadecuado del fármaco acenocumarol en la fibrilación auricular no valvular. Métodos: Se realizó un estudio exploratorio, en un sistema de salud de atención primaria y hospitales de categoría secundaria. La población la integraron 2 650 habitantes del sureste español con fibrilación auricular no valvular, tomadores de acenocumarol con seguimiento de 12 meses. Resultados: Se consideró las variaciones y labilidad del valor International Normalized Ratio, entre 2,0-3,0 en determinaciones cada 28 días, no obstante a la enfermedad cardiovascular y cifras obtenidas respecto a las anteriores. El tiempo de seguimiento fue 12 meses y desapareció la fragilidad, se tomaron muestras cada 28 días. Antes de finalizar el estudio, desapareció la labilidad del International Normalized Ratio durante más de tres meses en 53 (97,95 %) de los pacientes. Dado que la mayoría de los enfermos que consumían acenocumarol tenían edades por encima de 65 años y estaban sometidos a régimen de poli medicación, los medicamentos que consumían, fueron motivo de evaluación. Conclusiones: El tiempo transcurrido entre la determinación del International Normaizedl Ratio y la última ingesta de alimentos y medicamentos, no fue correcto, existe tendencia a realizar determinaciones anárquicas del International Normalized Ratio, sin investigaciones relacionadas con fármacos consumidos junto al acenocumarol.

Introduction: The use of acenocoumarol as an anticoagulant represents a contribution to the treatment of non-valvular atrial fibrillation. At present, there are other types of anticoagulants that do not require such exhaustive control of the International Normalized Ratio digital test and have fewer side effects. Spain is one of the few countries in Europe that continues to prescribe acenocoumarol, which is similar to warfarin. So much so that primary care physicians are not allowed to prescribe other more effective and less troublesome anticoagulants for the patient when performing the digital test. Objective: To analyze the inappropriate use of the drug acenocoumarol in non-valvular atrial fibrillation. Methods: An exploratory study was carried out in a primary health care system and secondary category hospitals. The population consisted of 2650 inhabitants of southeastern Spain with non-valvular atrial fibrillation, taking acenocoumarol with 12 months follow-up. Results: We considered the variations and lability of the International Normalized Ratio value, between 2.0-3.0 in determinations every 28 days, regardless of cardiovascular disease and figures obtained in relation to the previous. The follow-up time was 12 months and the lability disappeared, samples were taken every 28 days. Before the end of the study, the lability of the International Normalized Ratio disappeared for more than three months in 53 (97.95%) of the patients. Since most of the patients taking acenocoumarol were over 65 years of age and on polymedication, the medications taken by each of them were evaluated. Conclusions: The time elapsed between the International Normalized Ratio determination and the last intake of food and medication was not correct, and there is a tendency to perform anarchic determinations of the International Normalized Ratio without investigations related to drugs consumed together with acenocoumarol.

Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique

Abstract This publication is an update of the "Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology" published in 2019, considering the novel, targeted-oriented systemic therapies for atopic dermatitis. The initial recommendations of the current consensus for systemic treatment of patients with atopic dermatitis were based on a recent review of scientific published data and a consensus was reached after voting. The Brazilian Society of Dermatology invited 31 experts from all regions of Brazil and 2 international experts on atopic dermatitis who fully contributed to the process. The methods included an e-Delphi study to avoid bias, a literature search and a final consensus meeting. The authors added novel approved drugs in Brazil and the indication for phototherapy and systemic therapy for AD. The therapeutical response to systemic treatment is hereby reported in a suitable form for clinical practice and is also part of this updated manuscript.

A pilot integrated qualification program to improve medication use in a long-term care facility: a hybrid effectiveness-implementation study

Objective: to describe the implementation and to assess the effectiveness of a pilot integrated qualification program to improve the medication use in a long-term care facility (LTCF). Methods: This was a type 1 hybrid effectiveness-implementation study. A pilot integrated qualification program to improve the medication use in a LTCF was carried out by implementing a new drug distribution system and a comprehensive medication management (CMM) service according to the following four steps: I) implementation of the drug distribution system followed by the evaluation of the health team's opinion; II) prescription review with the identification of potential drug therapy problems (PDTPs); III) provision of the CMM service according to the framework of Pharmaceutical Care practice within one year; and, IV) evaluation of the effectiveness of the program through the comparison of clinical and laboratory parameters (blood pressure, glycated hemoglobin and lipid fractions) using the t-test or Wilcoxon signed-rank test. Results: In step I, the distribution system was fully outsourced to a company that furnished all solid oral dosage forms in individual boxes containing a plastic coil with multiple envelopes for 30 days. In step II, 180 PDTPs were identified, and all patients presented with at least one of them. In step III, after the first assessment of the CMM Service, 43 actual drug therapy problems (DTPs) were identified. After one year of service provision, 96 DTPs were identified and 75.8% of them were resolved (n=72). In step IV, a statistically significant difference was observed between the initial and final minimum and maximum systolic and diastolic blood pressure (p<0,05). Conclusions: The pilot integrated qualification program had a positive impact on the clinical parameters. The global population is rapidly aging, making this type of study important to exemplify a multifaceted strategy to improve the quality of drug therapy for institutionalized patients.

Drug-related problems of hospitalized elderly patients with limited life expectancy / 中华全科医师杂志

Objective:To analyze drug-related problems (DRPs) of hospitalized elderly patients with limited life expectancy.Methods:A total of 261 patients aged ≥ 70 years with limited life expectancy according to the 1-year mortality prediction index, who were admitted in the geriatric ward of Peking Union Medical College Hospital from January 2015 to December 2021 were included. According to Strand system, the categories, medications and interventions of DRPs were analyzed.Results:Among 261 patients, 187 (71.6%) had 672 DRPs. The most common DRPs were related to drug safety, including 271 (40.3%) adverse drug reactions and 149 over dosages (22.2%). A total of 207 drugs were involved in DRPs, and the top 5 classes with higher frequency of DRPs were antiinfectives for systemic use(20.7%,139/672), nervous system drugs(19.4%,130/672), alimentary tract and metabolism drugs(16.5%,111/672), cardiovascular system drugs(16.1%,108/672), and blood and hemopoietic organs drugs(13.7%,92/672). The recommendations were given by pharmacists for all 672 DRPs, and 643 were accepted by physicians (95.7%). The therapy need to be adjusted in 564 recommendations and the medications need to be monitored in 108 recommendations. In recommendations of therapy adjustment, 49.6%(280/564) were related to deprescribing. The deprescribing with higher frequency included antiinfectives for systemic use(29.6%, 83/280), lipid modifying agents(7.9%,22/280) and antithrombotic agents(7.9%,22/280). Patients with severe disability had significantly higher average DRPs(2 vs. 1) and average deprescribing(1 vs. 0) than patients without severe disability( Z=-4.83, Z=-3.61, all P<0.001). Conclusion:Drug safety is the most common DRP in limited life expectancy elderly inpatients, particularly for those with severe disability.

Volume residual de frascos-ampola e subdosagens de medicamentos preparados pela equipe de enfermagem / Residual volume of ampoule-vials and underdosing of medications prepared by a nursing staff / Volumen residual de frascos ampolla y subdosificación de medicamentos preparados por el equipo de enfermería

RESUMO Objetivo: Identificar o volume residual em frascos-ampola, após o preparo de injetáveis, associando os erros relacionados a subdoses com as classes dos medicamentos. Método: Estudo descritivo, de abordagem quantitativa. Os dados foram coletados no período de dezembro de 2020 a setembro de 2021, em um serviço ambulatorial privado de um município brasileiro localizado a nordeste do Estado de São Paulo. Foram analisados 562 frascos-ampola de medicamentos preparados pela equipe de enfermagem. Utilizou-se formulário contendo o nome comercial do medicamento, classe/indicação terapêutica, data e horário de reconstituição, volume utilizado para reconstituição do medicamento e volume residual de cada frasco. Os dados foram tabulados e analisados por estatística descritiva e teste ANOVA. Resultados: 462 (82,2%) frascos-ampola continham volume residual que variou de 0,1 ml a 1,5 ml e 165 (29,4%) continham 0,2 ml de solução residual, com perda média de 4,5% da solução. Não houve diferença na perda de solução entre as diferentes classes de medicamentos. Conclusão: Os achados destacam a necessidade de intervenções para a redução de falhas, nas fases de preparo dos medicamentos, com ênfase nos erros associados às subdosagens terapêuticas.

ABSTRACT Objective: Identify the residual volume in ampoule-vials after the preparation of injectables, associating the errors related to underdosing with the classes of drugs. Method: This is a descriptive study with a quantitative approach. Data were collected between December 2020 and September 2021, in a private outpatient service located in a Brazilian municipality in the northeast of the state of São Paulo. A total of 562 ampoule-vials of medications prepared by a nursing staff were analyzed. A form was used containing the commercial name of the medication, therapeutic class/indication, reconstitution date and time, volume used to reconstitute the medication and residual volume of each vial. The data were tabulated and analyzed using descriptive statistics and the ANOVA test. Results: the residual volume of 462 (82.2%) ampoule-vials varied between 0.1 ml and 1.5 ml, whereas 165 (29.4%) ampoule-vials had 0.2 ml of residual volume, with a mean loss of 4.5% of the solution. There was no difference in the loss of solution between the different classes of drugs. Conclusion: The findings highlight the need for interventions to reduce failures in the medication preparation phases, with emphasis on errors associated with therapeutic underdosing.

RESUMEN Objetivo: Identificar volúmenes residuales en frascos ampolla luego de prepararse inyectables, asociando los errores relacionados a subdosificaciones con las clases de los medicamentos. Método: Estudio descriptivo, de abordaje cuantitativo. Datos recolectados entre diciembre de 2020 y setiembre de 2021 en servicio ambulatorio privado de un municipio brasileño del noreste del Estado de São Paulo. Fueron analizados 562 frascos ampolla de medicamentos preparados por el equipo de enfermería. Se utilizó formulario, consignando nombre comercial del medicamento, clase/indicación terapéutica, fecha y hora de reconstitución, volumen utilizado para reconstituir el medicamento y volumen residual de cada frasco. Los datos fueron tabulados y analizados por estadística descriptiva y test ANOVA. Resultados: 462 (82,2%) frascos ampolla contenían volumen residual de entre 0,1 ml y 1,5 ml, y 165 (29,4%) contenían 0,2 ml de solución residual, con una pérdida media del 4,5% de solución. No se observó diferencia de pérdida de solución entre las diferentes clases de medicamentos. Conclusión: Los hallazgos destacan la necesidad de intervenciones para reducir fallos en las fases de preparación de medicamentos, haciendo énfasis en los errores asociados con subdosificaciones terapéuticas.

O sujeito e seu cuidado: a questão da adesão à medicação / The subject and his care: the issue of medication adherence

Resumo O mapeamento dos comportamentos frente ao uso de medicamentos informa as condições pelas quais um tratamento farmacológico é implementado. A localização da adesão à medicação como um problema clínico, evoca, no entanto, lugares bem demarcados quanto aos procedimentos para sua explicação e resolução. Nesse sentido, este trabalho busca problematizar os elementos fundantes do estudo da adesão à medicação, considerando que tal prática é hegemonicamente assimilada apenas por parâmetros científicos e biológicos, sem a inclusão de uma abordagem direcionada às especificidades históricas e culturais dos pacientes. Transferem-se, assim, a primazia da delimitação e a explicação da realidade ao próprio analista. Porém, o trabalho de campo demonstrou uma diversidade de posturas e agenciamentos quanto ao uso dos medicamentos, capaz de indicar que a geografia do cuidado não se orienta apenas a partir de um percurso linear, mas se apoia em espaços ambulantes e itinerantes, instalando-se em um campo paradoxal que mescla reprodução e criação.

Abstract The mapping of behaviors towards the use of medicines informs the conditions under which a pharmacological treatment is implemented. However, the location of medication adherence as a clinical problem evokes well-demarcated place as to the procedures for its explanation and resolution. In this sense, this work aims to problematize the founding elements of the study of medication adherence, considering that such practice is hegemonically assimilated only by scientific and biological parameters, without the inclusion of an approach directed to the patients' historical and cultural specificities. In this way, the primacy of delimitation and explanation of reality is transferred to the analyst. However, the field work showed a diversity of attitudes and management of medicines, capable of indicating that the geography of care is not oriented only from a linear path, but is supported by wandering and itinerant spaces, installing in a paradoxical field that mixes reproduction and creation.

Potentially inappropriate medication use in a comprehensive therapy management service: clinical outcomes and interventions

Abstract This study aimed to describe potentially inappropriate medication (PIM) use according to the Beers criteria among older adults followed in a comprehensive medication management (CMM) service, the pharmacists´ interventions, and the clinical outcomes of PIM use. All older adults in a CMM service delivered in the Brazilian public primary care system were included in the study (n = 389). Two methodological approaches were developed: (I) cross-sectional - prevalence of PIM use and associated factors were identified (univariate analysis - Pearson's chi-square; multivariate - logistic regression); (II) documental analysis of the negative clinical outcomes potentially associated with PIM use and pharmacists' interventions. The prevalence of PIM use was 48.3%, and it was independently and positively associated with the use of ≥ 5 drugs. For 21.3% of PIMs, a potential negative clinical outcome was identified. The most common negative clinical outcome was hypotension (35.1% of the negative outcomes), fractures or diagnosis of osteoporosis (21.1%), and hypoglycemia (14.0%). For most of them (78.9%), an intervention was performed to mitigate harm or discontinue use. A high prevalence of PIM was detected and was associated with polypharmacy. A significant proportion of PIM showed potential negative clinical outcomes that were identified by clinical pharmacists, and the majority of pharmacists' interventions aimed at its mitigation or deprescription. Overall, our findings reinforce the potential of CMM services for reducing PIM use and the occurrence of negative outcomes.

Molluscum Contagiosum Associated with Acquired Immunodeficiency Syndrome: Experience in HIV outpatient care and literature review / Molusco contagioso associado à síndrome da imunodeficiência adquirida: experiência no atendimento em ambulatório de HIV e revisão da literatura

Introduction: Molluscum contagiosum is a dermatosis caused by a DNA virus of the family Poxvirus and genus Molluscipoxvirus, affecting mainly children, sexually active adults, atopic individuals and immunocompromised patients, especially those with human immunodeficiency virus (HIV) infection. Objective: To describe our experience in caring for patients living with HIV who presented with extensive and severe Molluscum contagiosum, and to conduct a literature review on the subject as well. Methods: An electronic search was carried out in the MEDLINE/PubMed and SciELO databases and in the books: ATLAIDS and AZULAY limited to the period of January 2017 to June 2021. Results: Four clinical cases are reported in people living with HIV with extensive lesions normally not found in immunocompetent patients. The treatment performed in the cases reported in this article was the punctual application of 90% trichloroacetic acid (TCA) to each lesion, with complete remission of the clinical presentation in two patients over a period of three and six months. The other two patients did not receive treatment for molluscum contagiosum as they died because of pulmonary complications. Conclusion: Infection with Molluscum contagiosum in people living with HIV has disseminated forms with large-volume lesions, with substantial stigmatizing aesthetic impairment, and treatment with 100% TCA is quite effective.

Introdução: Molusco contagioso é uma dermatose causada por um vírus de DNA da família poxvírus e do gênero Molluscipoxvirus. Afeta principalmente crianças, adultos sexualmente ativos, indivíduos atópicos e pacientes imunodeprimidos, especialmente aqueles com infecção pelo vírus da imunodeficiência humana (HIV). Objetivo: Descrever a experiência no atendimento de pacientes vivendo com HIV que apresentaram quadro de molusco contagioso extenso e grave, além de realizar uma revisão da literatura sobre o tema. Métodos: Foi realizada uma pesquisa eletrônica nas bases de dados MEDLINE/PubMed e SciELO e nos livros ATLAIDS e AZULAY, limitada ao período de janeiro de 2017 a junho de 2021. Resultados: São relatados quatro casos clínicos em pessoas que vivem com HIV com lesões extensas normalmente não encontradas em pacientes imunocompetentes O tratamento realizado nos casos relatados nesse artigo foi a aplicação pontual de ácido tricloroacético (ATC) 100% em cada lesão, com a remissão completa do quadro clínico em dois pacientes em um período de tempo entre três e seis meses. Os outros dois pacientes não receberam tratamento para o vírus do molusco contagioso pois evoluíram para óbito em razão de complicações pulmonares. Conclusão: A infecção pelo molusco contagioso em pessoas vivendo com HIV apresenta formas disseminadas com lesões de grande volume, com comprometimento estético estigmatizante importante, e o tratamento com ATC 90% é bastante eficaz.

Insulinoterapia en pacientes con diabetes mellitus tipo 2. Una revisión narrativa / Insulin based therapy in patients with type 2 diabetes mellitus. A narrative review / Insulinoterapia em pacientes com diabetes mellitus tipo 2. Uma revisão narrativa

RESUMEN Introducción La diabetes mellitus tipo 2 (DM2), es una de las enfermedades crónicas no transmisibles que ha aumentado su incidencia en las últimas décadas en todo el mundo, siendo su tratamiento pautas y esquemas de insulinoterapia. No obstante, la gran disponibilidad comercial y el control glucémico atribuido a la insulinoterapia ha generado múltiples confusiones en los usuarios y el personal de salud. Objetivo Describir las pautas y esquemas en el tratamiento de la DM2. Desarrollo La evolución tecnológica de la insulinoterapia conlleva el uso de múltiples análogos. Dentro de estos destacan los inhalatorios y premezclas por su eficacia en el control glucémico a través del tiempo, considerando las pautas de administración subcutánea en estas premezclas una serie de elementos como la zona de punción, seguridad y uso de pliegues. Dichas pautas han inducido la creación de diversos esquemas de insulinoterapia entre los que se destacan los métodos de acción intensiva y acción móvil, orientados a la simulación de la insulina fisiológica como mecanismo de acción para el control glucémico. La seguridad de estos mecanismos depende del sistema público de salud chileno para la dosificación, administración y control suministrado. Conclusión Las pautas y esquemas de insulinoterapia sugieren el uso de análogos de acción prolongada ante hiperglucemia; su uso requiere conocimiento integral de los pacientes y cuidadores con el fin de evitar efectos adversos. Los hallazgos de esta revisión deben ser considerados con cautela al momento de tomar decisiones clínicas producto de las limitaciones metodológicas propias del diseño utilizado.

ABSTRACT Introduction Type 2 diabetes mellitus is one of the non transmissible chronic illnesses which have increased in prevalence during the last decades worldwide. Among the related treatments is the insulin based therapy. Nevertheless, the multiple and diverse controlled and commercial options of this therapy have generated confusion among both the users and health staff. Objective To describe some insulin-based therapy approaches to type 2 diabetes mellitus. Development The related technological advances have produced new diverse analog forms of insulin-based therapies. Among these, inhaling and blended forms can be highlig- hteddue to their efficacy in glucose control. Among the blended mixture, administration forms are the intensive action and the mobile action ones, which can use a human insulin analog as the key therapy element. The public systems, including the Chilean, have an important security role in the supervision and monitoring of the proper and correct dose administrations. Conclusion The diverse forms of insulin-based therapies for patients with type 2 diabetes mellitus include those with prolonged action insulin analogs but their use should be based on integral knowledge in order to avoid adverse effects. The findings of this review should be considered with caution due to the methodological limitations derived from the study design.

RESUMO Introdução O diabetes mellitus tipo 2 (DM2), é uma das doenças crônicas não transmissíveis que tem aumentado sua incidência nas últimas décadas no mundo todo, sendo suas diretrizes de tratamento e esquemas de insulinoterapia. No entanto, a grande disponibilidade comercial e o controle glicêmico atribuído à insulinoterapia têm gerado múltiplas confusões em usuários e profissionais de saúde. Objetivo Descrever as diretrizes e esquemas no tratamento do DM2. Desenvolvimento A evolução tecnológica da insulinoterapia envolve o uso de múltiplos análogos. Dentre estes, os inalantes e pré-misturas destacam-se por sua eficácia no controle glicêmico ao longo do tempo, considerando as orientações de administração subcutânea nessas pré-misturas uma série de elementos como área de punção, segurança e uso de dobras. Essas diretrizes levaram à criação de diversos esquemas de insulinoterapia, dentre os quais se destacam os métodos de ação intensiva e ação móvel, visando simular a insulina fisiológica como mecanismo de ação para o controle glicêmico. A segurança desses mecanismos depende do sistema de saúde pública chileno para a dosagem, administração e controle fornecidos. Conclusão Diretrizes e esquemas de insulinoterapia sugerem o uso de análogos de longa ação na hiperglicemia; seu uso requer conhecimento abrangente dos pacientes e cuidadores a fim de evitar efeitos adversos. Os achados desta revisão devem ser considerados com cautela ao tomar decisões clínicas devido às limitações metodológicas do desenho utilizado.

Condutas clínicas e barreiras no tratamento da polineuropatia amiloidótica familiar associada à transtirretina (PAF-TTR) no Brasil / Clinical practice and barriers in familial transthyretinrelated amyloidotic polyneuropathy (FAP) care in Brazil

Objetivo: Identificar as condutas terapêuticas e a variabilidade na prática clínica, assim como necessidades não atendidas e barreiras para a adequada assistência a pacientes com polineuropatia amiloidótica familiar relacionada à transtirretina (PAF-TTR), no Brasil. Métodos: Estudo transversal, por meio de questionário semiestruturado on-line enviado por e-mail. Foram incluídos médicos com experiência no manejo clínico-assistencial de pacientes com PAF-TTR no Brasil. O questionário foi composto por 30 questões envolvendo características gerais da população brasileira com PAF-TTR, características das escolhas terapêuticas e da falha, definições de progressão de doença e estadiamento, e métodos para mensuração do impacto na qualidade de vida. Resultados: Seis profissionais responderam ao inquérito. Quanto ao diagnóstico e à classificação da doença, houve consenso quanto ao uso de quadro clínico associado a testagem genética para o diagnóstico, e foram considerados adequados os critérios de Coutinho e do Ministério da Saúde, apesar de serem pouco úteis na avaliação da progressão da doença. Entre os especialistas, 83,3% entendem que a terapia atualmente disponível no Sistema Único de Saúde (SUS) atende às necessidades dos pacientes no estágio I da doença, entretanto todos os especialistas apontam necessidades assistenciais não atendidas, uma vez que esse medicamento não possui benefício definido para os estágios II e III da doença. A progressão da doença é definida como qualquer novo sintoma ou piora daqueles preexistentes, não sendo necessária modificação no estágio da doença para caracterizar tal evento. Conclusões: A condução deste estudo permitiu a identificação de aspectos importantes para auxiliar no entendimento da prática clínico-assistencial no país e das necessidades em saúde desses pacientes

Objective: To identify therapeutic approaches and variability in clinical practice, as well as unmet needs and barriers to adequate care for patients with familial transthyretin-related amyloidotic polyneuropathy (FAP) in Brazil. Methods: Cross-sectional study using an online semi-structured questionnaire sent by email. Physicians with experience in the clinical-care management of patients with FAP in Brazil were included. The questionnaire consisted of 30 questions involving general characteristics of the Brazilian population with FAP; characteristics of therapeutic choices and failure; definitions of disease progression and staging; and methods for measuring the impact on quality of life. Results: Six professionals responded to the survey. As for the diagnosis and classification of the disease, there was a consensus regarding the use of a clinical picture associated with genetic testing for the diagnosis and, as appropriate, the criteria proposed by Coutinho and the Ministry of Health, although not very useful in evaluating the progression of the disease. 83.3% of experts understand that the therapy currently available in the SUS meets the needs of patients in stage I of the disease, however, all experts point out unmet care needs, since this drug has no defined benefit for stages II and III of the disease. Disease progression is defined as any new symptom or worsening of pre-existing ones, and no change in the stage of the disease is necessary to characterize such an event. Conclusions: The conduction of this study allowed to identify important aspects to a better understanding of the clinical care practice in the country and unmet needs of these patients

Toxicodermia as an adverse event in a covid-19 patient: case report

ABSTRACT: Introduction: SARS-COV2 infection, which was initially associated with respiratory manifestations only, can also cause gastrointestinal, kidney, neurological and cardiovascular symptoms according to some reports. Case presentation: A 36-year-old female patient attended the emergency department due to dyspnea, asthenia, adynamia, mild odynophagia. and headache. The patient's medical history included obesity, smoking, and working as a health care worker. Considering the symptoms, antimalarial and antiretroviral treatment was indicated to treat COVID-19, a diagnosis that was confirmed three days after admission. However, on the fourth day of treatment, the patient presented with polydipsia and macular, pruritic, and generalized rash. Due to suspicion of toxicoderma, the treatment was suspended, and the skin condition improved. After 8 days of hospitalization, the patient was discharged with biosecurity recommendations and mandatory isolation for 28 days. Conclusion: The described case is a report of toxicoderma in a patient with COVID-19 under treatment with antiretroviral and antimalarial drugs. Based on the findings, a thorough examination of skin and mucosa of patients with suspected or confirmed COVID-19 will undoubtedly contribute to the correct characterization of this new disease.

RESUMEN Introducción. La infección por SARS-COV2, que en principio se pensó solo causaba manifestaciones respiratorias, también puede ocasionar síntomas gastrointestinales, renales, neurológicos, cardiovasculares e incluso cutáneos según algunos reportes. Presentación del caso. Paciente femenina de 36 años quien asistió al servicio de urgencias por cuadró clínico consistente en disnea, astenia, adinamia, odinofagia leve y cefalea. Como antecedentes de relevancia se registró obesidad, tabaquismo y ocupación como trabajadora de la salud. Dados los síntomas, se indicó tratamiento antimalárico y antirretroviral para tratar COVID-19, diagnóstico que fue confirmado a los tres días de ingreso, pero al cuarto día de instaurado este manejo la mujer presentó polidipsia y rash macular, pruriginoso y generalizado. Por sospecha de toxicodermia, el tratamiento fue suspendido y con esto el cuadro cutáneo mejoró. Luego de 8 días de hospitalización, la paciente recibió el alta, junto con recomendaciones de bioseguridad y confinamiento durante 28 días. Conclusiones. El caso descrito corresponde a un evento de toxicodermia en una paciente con COVID-19 en manejo con antirretroviral y antimalárico. A partir de los hallazgos, se establece que la exploración minuciosa de piel y mucosas en los pacientes con sospecha o diagnóstico confirmado de COVID-19 puede ser de gran ayuda para la correcta caracterización de esta nueva enfermedad.

Gestão Autônoma da Medicação, do Quebec ao Brasil: uma aposta participativa / Gaining Autonomy & Medication Management, from Quebec to Brazil: a participatory commitment

RESUMO Este artigo apresenta o contexto e os modos de construção da versão brasileira do Guia da Gestão Autônoma da Medicação (Guia GAM-BR), comparativamente ao Guia originário do Quebec. O Guia GAM-BR foi resultado de parceria estabelecida entre Brasil e Canadá que, por meio de uma pesquisa multicêntrica, transpôs ao contexto brasileiro o instrumento quebequense, a serviço dos usuários da saúde mental, visando ao aumento do seu poder de negociação em seus tratamentos medicamentosos. Tal transposição implicou mais do que 'adaptação': tratou-se da 'transformação' do Guia originário em um instrumento brasileiro. Entre essas transformações, destacam-se: substituição do 'eu' pelo 'você' como sujeito do enunciado das questões apresentadas pelo Guia; maior desenvolvimento do tema dos direitos; supressão das orientações para retirada progressiva da medicação. Além disso, o dispositivo grupal fez-se imanente à estratégia GAM brasileira. Longe de significar traição, tais transformações mantêm-se fiéis à forma participativa e cogestiva que orientou a elaboração da GAM na sua origem, como encarnação da experiência democrática e cidadã própria ao Quebec. Assim, o artigo busca colocar em análise a produção dos efeitos da estratégia GAM em solo brasileiro, na consideração à experiência democrática e ao processo de reforma psiquiátrica no Brasil.

ABSTRACT This article presents the context and construction of the Brazilian version of the Gaining Autonomy & Medication Management Guide (GAM-BR) compared to Quebec's original Guide. The GAM-BR Guide resulted from a partnership between Brazil and Canada, which transposed the Quebec instrument to the Brazilian context through multicenter research to empower mental health users in the negotiation of their drug treatment. This process was more than an adaptation as it transformed the original Guide into a Brazilian instrument. The main changes were replacing 'I' with 'you' as the subject of the statements in the Guide, further developing the theme of rights, suppressing the guidelines for the progressive withdrawal of medication. Additionally, the group device became immanent to the Brazilian GAM strategy. Far from being a betrayal, this set of changes remains loyal to the participatory and co-managerial process that oriented the elaboration of the GAM at its origin as an embodiment of Quebec's typical democratic and citizen experience. Therefore, this article aims to analyze the production of the GAM strategy's effects of in Brazil, considering its democratic experience and the psychiatric reform in the country.

Assistência de Enfermagem aos pacientes com extravasamento de medicamentos antineoplásicos: revisão integrativa / Nursing care for patients with extravasation of antineoplastic drugs: an integrative review

Objetivo: Identificar as ações realizadas pela equipe de enfermagem no extravasamento de drogas antineoplásicas. Método: revisão integrativa de artigos científicos publicados em periódicos nacionais e internacionais, de 2015 a 2020.Resultados: foram identificadas 287 publicações, após a seleção e elegibilidade foram incluídos 5 artigos. Foram extraídas as recomendações gerais e específicas relacionadas ao extravasamento de drogas antineoplásicas. Conclusão: O extravasamento é uma complicação grave durante o tratamento quimioterápico, que pode afetar sua continuidade. Entre as competências da enfermagem estão as ações de prevenção, identificação e o manejo deste evento adverso.

Objective: To identify the actions taken by the nursing team in the ex­travasation of antioneoplastic drugs. Method: integrative review of scientific articles published in national and international journals, from 2015 to 2020. Results: 287 publications were identified, after selection and eligibility 5 articles were included. The general and specific recommendations related to the extravasation of antineoplastic drugs were extracted. Conclusion: Extravasation is a serious complication during chemotherapy, which can affect its continuity. Among the skills of nursing are the actions of prevention, identification and management of this adverse event.

Rodízio de Opioides: uma Análise Descritiva / Opioid Switching: a Descriptive Analysis / Rotación de Opioides: un Análisis Descriptivo

Introdução: O uso de opioides deve ser individualizado e a troca por outro opioide pode ser necessária (rodízio de opioide). Objetivo: Identificar como foi realizado o rodízio de opioide e se o efeito desejado foi atingido em pacientes internados em uma unidade especializada em cuidados paliativos oncológicos. Método: Análise post hoc do estudo de perfil de pacientes internados em um hospital público de cuidados paliativos oncológicos no Rio de Janeiro, entre setembro e novembro de 2016. As internações foram acompanhadas longitudinalmente por revisão de prontuário com coleta diária da escala verbal numérica (EVN). A dor foi considerada controlada quando EVN = 0. Doses, via de administração e rodízio (fármaco e motivo) dos opioides foram observados. O tempo para controle da dor foi calculado quando este foi o motivo. Resultados: Foram observados 104 rodízios de opioides em 90 internações (22,5%), sendo 49% entre opioides fortes e 43% de fraco para forte. Principais motivos foram dor (40%) e dispneia (36%). O tempo para EVN = 0 foi 1,6 dias (+/-1,8; IC95% 1,0-2,1), sendo mais demorado na troca por metadona (média 2,7 dias +/-2,5; IC95% 1,0-4,4). Comparando a dose de morfina oral por equipotência analgésica, houve aumento de 10% na dose do opioide de destino, sendo esse aumento maior quando no rodízio por dispneia (38%). Conclusão: Embora o controle de dor tenha sido superior ao descrito por outros trabalhos, o aumento da dose equipotente do opioide não é corroborado por protocolos. Maior vigilância e outros estudos são recomendados na unidade.

Introduction: The use of opioids must be individualized and changing for another opioid may be necessary (opioid switching). Objective: Identify how the opioid switching was performed and whether the desired effect was achieved in patients admitted at a public palliative oncologic care specialized hospital. Method: Post hoc analysis of the profile study of patients admitted to a public oncologic palliative care hospital in Rio de Janeiro between September and November 2016. Hospitalizations were followed longitudinally by reviewing the charts with daily collection of the numeric rating scale (NRS). Pain was considered controlled when NRS = 0. Doses, route of administration, switch (drugs and motif ) of the opioids were observed. The time for pain control was calculated when this was the reason. Results: 104 opioid switching were observed in 90 hospitalizations (22.5%), 49% of which were strong opioids and 43%, from mild to strong. Main reasons were pain (40%) and dyspnea (36%). The time to NRS = 0 was 1.6 days (+/-1.8; 95% CI 1.0-2.1), taking longer to switch to methadone (mean 2.7 days +/-2.5; 95% CI 1.0-4.4). Comparing the dose of oral morphine by analgesic equipotency, a 10% increase in the target opioid dose occurred, and when rotating due to dyspnea (38%), the increase was greater. Conclusion: Although pain control was higher than described in other studies, the increase in the equipotent dose of opioid is not corroborated by protocols. Extensive surveillance and other studies are recommended in the unit.

Introducción: El uso de opioides debe ser individualizado y puede ser necesario cambiarlo por otro opioide (rotación de opioides). Objetivo: Identificar cómo se realizó la rotación de opioides y si el efecto deseado se logró en pacientes ingresados en una unidad especializada en cuidados oncológicos paliativos. Método: Análisis post hoc del estudio de perfil de pacientes ingresados en un hospital público de cuidados paliativos de oncología en Río de Janeiro, entre septiembre y noviembre de 2016. Las hospitalizaciones fueron seguidas longitudinalmente mediante la revisión de los registros médicos con la recopilación diaria de la Escala Numérica Verbal (ENV). El dolor se consideró controlado cuando ENV = 0. Se observaron dosis, vía de administración, rotación (fármacos y motivo) de los opioides. El tiempo para el control del dolor se calculó cuando esta fue la razón. Resultados: Se observaron 104 ruedas de opioides en 90 hospitalizaciones (22,5%), con 49% entre opioides fuertes y 43% de débiles a fuertes. Las razones principales fueron dolor (40%) y disnea (36%). El tiempo para ENV = 0 fue de 1,6 días (+/-1,8; IC del 95%: 1,0-2,1), y tomó más tiempo cambiar a metadona (promedio 2,7 días +/-2,5; IC 95% 1,0-4,4). Comparando la dosis de morfina oral para la equipotencia analgésica, hubo un aumento del 10% en la dosis de opioides objetivos, este aumento fue mayor al rotar debido a la disnea (38%). Conclusión: Aunque el control del dolor fue superior al descrito por otros estudios, el aumento en la dosis equipotente de opioide no es compatible con los protocolos. Se recomienda mayor vigilancia y otros estudios en la unidad.

Impact of the 21-Gene Recurrence Score (Oncotype DX®) on adjuvant therapy decision-making: a collaborative multicenter cohort study from Argentina

Introduction: At present, more than half of patients diagnosed with early-stage breast cancer (BC) and express hormonal receptors will receive some adjuvant chemotherapy scheme, but only a few of them would benefit in terms of survival. Genomic platforms allow a better understanding of the heterogeneity of different types of hormonal receptor-positive and HER2-negative BC. They have proven their validity as tools to identify those patients who will obtain a clear benefit with the indication of chemotherapy treatment. The aim of this study is to analyze the use of the genomic platform, namely, Oncotype Dx® and its impact on the indication of adjuvant treatment, evaluated mainly as the change in treatment indication. Methods: Multicenter observational cohort study was performed in different Mastology units in Argentina. Patients underwent the Oncotype Dx to clarify the adjuvant treatment. Treatment decisions were settled before and after performing Oncotype Dx. Results: From January 2013 to December 2018, 211 patients with luminal A or B and HER2-negative breast carcinomas, who underwent the Oncotype Dx, were included. Based on our records, 40% of the patients change the indication of adjuvant treatment after the performance of the Oncotype Dx. Of these, 24% of patients who underwent initial endocrine therapy only adjusted their treatment with the addition of chemotherapy. Among patients with an initial CTH recommendation, 49% were able to receive endocrine therapy only when, due to traditional prognostic factors, they would have received chemotherapy. Conclusions: In our population, the use of the Recurrence Score was clinically significant in relation to the change of the established treatments. Consequently, it is a very important tool and a decisive factor in the adjuvant indication in patients with positive hormonal receptors and HER2neu-negative early BC.